再次血运重建率在西罗莫司和紫杉醇的两个临床试验类似，分别为5.6%和5.3%。
Revascularization rates were similar with the sirolimus - and paclitaxel-eluting stents in the two trials, at 5.6% versus 5.3%, respectively.
Kushwaha和他的同事试验西罗莫司作为可选择的抗增值免疫抑制药物的使用。
Kushwaha and colleagues tested the use of sirolimus as an alternative anti-proliferative immunosuppressant drug.
这项先导试验是设计用来评估西罗莫司用于肾功不全肝移植受体的安全性和有效性的。
This pilot trial was designed to assess the safety and efficacy of SRL in liver transplant recipients with renal dysfunction.
应用推荐